DR info

Clinical trials : 39 / Drugs : 38 - (DrugBank : 7) / Drug target genes : 27 - Drug target pathways : 95

Drugs and their primary sponsors and trial info

(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2-yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate
   Clementia Pharmaceuticals Inc, an Ipsen Company
      2022   Phase 2   EUCTR2020-002858-24-SE   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-002858-24-ES   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2020-002858-24-NL   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2020-002858-24-DE   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
(R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4- yl)pyridine-2yl)pyrrolo[1,2-b]pyridazin-4-yl)piperazine-1-carboxylate
   CLEMENTIA PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-002858-24-IT   Argentina;Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
AZD0530
   VU University Medical Center
      2020   Phase 2   EUCTR2019-003324-20-NL   Netherlands;
AZD0530 Difumarate
   VU University Medical Center
      2020   Phase 2   NCT04307953   Germany;Netherlands;United Kingdom;
DS-6016a
   Daiichi Sankyo Co., Ltd.
      2021   Phase 1   NCT04818398   Japan;
Garetosmab
   Regeneron Pharmaceuticals
      2021   Phase 3   NCT04577820   -
INCB000928
   Incyte Corporation
      2021   Phase 2   NCT05090891   -
INCB000928 fumarate dihydrate
   Incyte Corporation
      -   Phase 2   EUCTR2021-002286-17-FR   Australia;Brazil;Canada;France;Germany;Korea, Republic of;Netherlands;Russian Federation;United Kingdom;United States;
      -   Phase 2   EUCTR2021-002286-17-DE   Australia;Brazil;Canada;France;Germany;Korea, Republic of;Netherlands;Russian Federation;United Kingdom;United States;
IPN60120
   Ipsen Pharma
      -   Phase 3   EUCTR2021-002244-70-SE   Argentina;Australia;Brazil;Canada;France;Italy;Spain;Sweden;United Kingdom;United States;
   Ipsen Pharma SAS
      -   Phase 3   EUCTR2021-002244-70-FR   Argentina;Australia;Brazil;Canada;France;Italy;Spain;Sweden;United Kingdom;United States;
IPN60130
   Clementia Pharmaceuticals Inc.
      2021   Phase 2   NCT05039515   France;Italy;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
IPN60130 10 mg capsules
   CLEMENTIA PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-002858-24-IT   Argentina;Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
   Clementia Pharmaceuticals Inc, an Ipsen Company
      2022   Phase 2   EUCTR2020-002858-24-SE   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-002858-24-ES   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2020-002858-24-NL   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2020-002858-24-DE   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
IPN60130 50 mg capsules
   CLEMENTIA PHARMACEUTICALS INC.
      2021   Phase 2   EUCTR2020-002858-24-IT   Argentina;Australia;Brazil;Canada;China;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
   Clementia Pharmaceuticals Inc, an Ipsen Company
      2022   Phase 2   EUCTR2020-002858-24-SE   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-002858-24-ES   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2020-002858-24-NL   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2   EUCTR2020-002858-24-DE   Argentina;Australia;Brazil;Canada;China;Colombia;France;Germany;Italy;Japan;Korea, Republic of;Mexico;Netherlands;Russian Federation;Spain;Sweden;United Kingdom;United States;
Midazolam
   Clementia Pharmaceuticals Inc.
      2019   Phase 1   NCT04829773   United States;
PALOVAROTENE -
   Clementia Pharmaceuticals Inc
      -   Phase 3   EUCTR2017-002541-29-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Japan;Netherlands;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States;
PALOVAROTENE-
   CLEMENTIA PHARMACEUTICALS INC.
      2018   Phase 3   EUCTR2017-002541-29-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Japan;Korea, Democratic People's Republic of;Korea, Republic of;Netherlands;Russian Federation;South Africa;Spain;Sweden;United Kingdom;United States;
Palovarotene
   Clementia Pharmaceuticals Inc.
      2019   Phase 1   NCT04829773   United States;
      2017   Phase 3   NCT03312634   Argentina;Australia;Brazil;Canada;France;Italy;Japan;Spain;Sweden;United Kingdom;United States;
      2016   Phase 2   NCT02979769   France;
      2015   Phase 2   NCT02521792   France;United Kingdom;United States;
      2015   Phase 2   EUCTR2014-002496-28-GB   Argentina;Australia;United Kingdom;United States;
      2014   Phase 2   NCT02190747   France;United Kingdom;United States;
      -   Phase 2   EUCTR2016-002526-36-FR   France;
   Ipsen
      2022   Phase 3   NCT05027802   -
Palovarotene dose level 1
   Clementia Pharmaceuticals Inc.
      2014   Phase 2   NCT02279095   Argentina;Australia;France;United Kingdom;United States;
Palovarotene dose level 2
   Clementia Pharmaceuticals Inc.
      2014   Phase 2   NCT02279095   Argentina;Australia;France;United Kingdom;United States;
Palovarotene dose level 3
   Clementia Pharmaceuticals Inc.
      2014   Phase 2   NCT02279095   Argentina;Australia;France;United Kingdom;United States;
Palovarotene dose level 4
   Clementia Pharmaceuticals Inc.
      2014   Phase 2   NCT02279095   Argentina;Australia;France;United Kingdom;United States;
Perhexiline
   Nagoya University Graduate School of Medicine
      2010   Phase 1,2   JPRN-UMIN000019348   Japan;
REGN2477
   REGENERON PHARMACEUTICALS, INC.
      2017   Phase 2   EUCTR2016-005035-33-IT   Argentina;Brazil;France;Italy;Netherlands;United Kingdom;United States;
   Regeneron Pharmaceuticals
      2018   Phase 2   NCT03188666   Canada;Colombia;France;Italy;Netherlands;Poland;Spain;United Kingdom;United States;
   Regeneron Pharmaceuticals, Inc.
      2019   Phase 2   EUCTR2016-005035-33-ES   Canada;Colombia;France;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
      2018   Phase 2   EUCTR2016-005035-33-NL   Argentina;Brazil;France;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-005035-33-GB   Canada;Colombia;France;Italy;Mexico;Netherlands;Poland;Spain;United Kingdom;United States;
SARACATINIB DIFUMARATE
   VU University Medical Center
      2020   Phase 2   EUCTR2019-003324-20-NL   Netherlands;